N-Acetyl Cysteine and Reduced Fatigue

Doses used in studies

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityNo significant difference60% on NAC versus 80% on placebo (p = 0.75)
At least one adverse event (AE) occurred in 60% on NAC versus 80% on placebo (p = 0.75).
from: A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.
abdominal painReported
There were two AEs attributed to NAC in one patient (abdominal pain and constipation)
from: A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.
constipationReported
There were two AEs attributed to NAC in one patient (abdominal pain and constipation)
from: A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.

1 of 1 paper

A pilot study of oxidative pathways in MS fatigue: randomized trial of N-acetyl cysteine.